BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once ...
Modeling simulations predict that transitioning to once every 4 weeks of lecanemab after 18 months will maintain clinical and biomarker therapy benefits. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV ...
STOCKHOLM, June 10, 2024 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
(RTTNews) - Eisai submitted to the U.S. Food and Drug Administration a Supplemental Biologics License Application or sBLA for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous or IV ...
KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), ...
Ultomiris (ravulizumab-cwvz) is a brand-name drug prescribed for certain autoimmune conditions. Ultomiris is given as an intravenous (IV) infusion by a healthcare professional. The drug’s dosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results